Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic.

"Declarations Conflict of interestThe authors declare no competing interests. Conflict of interest The authors declare no competing interests."

"Funding This work is supported by IGA_LF_2022_001, Ministry of Health of the Czech Republic–RVO (FNOL, 00098892), Czech Health Council grant AZV NU21-03–00386, Charles University Center of Excellence UNCE 204021, and National Institute for Cancer Research (ID LX22NPO5102) funded by the European Union-Next Generation EU, Programme EXCELES and PROGRES Q40/08 (FN HK)."

"This study was a part of the Observational Epidemiological and Clinical Study (NiHiL), ClinicalTrials.gov identifier NCT03199066. All the patients were treated according to the Declaration of Helsinki and provided written informed consent to their anonymous data processing before data entry. The study protocol was approved by the institutional ethics committee of the General University Hospital in Prague (retrospective analysis of the Czech Lymphoma Study Group [CLSG] registry)."